DDInter255 DDInter1321
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ocrelizumab
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) downregulates {v} (Gene) RALA
RALA {u} (Gene) is upregulated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) downregulates {v} (Gene) RALA
RALA {u} (Gene) is downregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) upregulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is upregulated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) upregulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is downregulated by {v} (Compound) Dactinomycin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan {u} (Compound) downregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Ocrelizumab
Busulfan {u} (Compound) downregulates {v} (Gene) CHEK2
CHEK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) downregulates RALA (Gene) and RALA (Gene) is upregulated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) downregulates RALA (Gene) and RALA (Gene) is downregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) upregulates TP53BP2 (Gene) and TP53BP2 (Gene) is upregulated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) upregulates TP53BP2 (Gene) and TP53BP2 (Gene) is downregulated by Dactinomycin (Compound) and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Busulfan (Compound) downregulates DNAJB2 (Gene) and DNAJB2 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Ocrelizumab
Busulfan (Compound) downregulates CHEK2 (Gene) and CHEK2 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab